Processing

Please wait...

Settings

Settings

Goto Application

1. WO1998034613 - QUINAZOLINONE-CONTAINING PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF NEOVASCULARIZATION AND FOR TREATING MALIGNANCIES

Publication Number WO/1998/034613
Publication Date 13.08.1998
International Application No. PCT/IL1998/000070
International Filing Date 11.02.1998
Chapter 2 Demand Filed 27.07.1998
IPC
A61K 31/517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
CPC
A61K 31/517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • AGRICULTURAL RESEARCH ORGANIZATION [IL]/[IL]
  • HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT COMPANY LTD. [IL]/[IL]
Inventors
  • PINES, Mark
  • NAGLER, Arnon
  • VLODAVSKY, Israel
  • MIAO, Hua-Quan
Agents
  • FRIEDMAN, Mark, M.
Priority Data
08/797,70311.02.1997US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) QUINAZOLINONE-CONTAINING PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF NEOVASCULARIZATION AND FOR TREATING MALIGNANCIES
(FR) COMPOSITIONS PHARMACEUTIQUES CONTENANT DE LA QUINAZOLINONE ET DESTINEES A LA PREVENTION DE LA NEOFORMATION DE VAISSEAUX SANGUINS ET AU TRAITEMENT D'AFFECTIONS MALIGNES
Abstract
(EN)
The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a coupound having a formula (I) wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy carbonyl; and pharmaceutically acceptable salts thereof; as active ingredient therein, in combination with a pharmaceutically acceptable carrier.
(FR)
L'invention concerne une composition destinée à atténuer la néoformation de vaisseaux sanguins et à traiter des affections malignes, et comprenant une dose efficace sur le plan pharmacologique d'un composé correspondant à la formule (I), ou de sels de celui-ci, acceptables sur le plan pharmacologique. Dans cette formule R1 est choisi dans le groupe constitué par hydrogène, halogène, nitro, benzo, alkyle inférieur, phényle et alcoxy inférieur, R2 est choisi dans le groupe constitué par hydroxy, acétoxy et alcoxy inférieur, et R3 est choisi dans le groupe constitué par hydrogène et alcénoxy inférieur-carbonyle. L'invention concerne l'utilisation de cette composition en tant que principe actif, en combinaison avec un excipient acceptable sur le plan pharmacologique.
Latest bibliographic data on file with the International Bureau